Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 12/20 | 0.76 |
| ▸ | AVPR1A | P37288 | 10/20 | 0.76 |
| ▸ | OXTR | P30559 | 5/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
| ▸ | CA7 | P43166 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 1/20 | 0.63 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243307 | 0.86 | AVPR2 (0.80) | AVPR2AVPR1AOXTRCA1CA2 | |
| SCHEMBL7347092 | 0.86 | AVPR2 (1.00) | AVPR2AVPR1AOXTRCA1CA2 | |
| SCHEMBL7349162 | 0.86 | AVPR1A (0.64) | AVPR2AVPR1AOXTR | |
| SCHEMBL7357300 | 0.85 | AVPR2 (0.97) | AVPR2AVPR1AOXTRCA1CA2 | |
| Hydrochloric Acid SCHEMBL4832640 | 0.85 | MEN1 (0.66) | AVPR2AVPR1AOXTRCA1CA2 | |
| SCHEMBL9389632 | 0.83 | AVPR2 (1.00) | AVPR2AVPR1AOXTRALDH1A1 | |
| SCHEMBL2128884 | 0.83 | AVPR2 (0.76) | AVPR2AVPR1AOXTRALDH1A1 | |
| SCHEMBL18944228 | 0.82 | AVPR2 (0.74) | AVPR2AVPR1AOXTRALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL5236491 | 0.82 | AVPR2 (0.65) | AVPR2AVPR1AOXTRALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL5237037 | 0.82 | ALDH1A1 (0.65) | AVPR2AVPR1AOXTRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778677-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | Ferring B.V. (NL) | 2007-05-02 | — | — | EP | claimed |
| WO-2006018443-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2006-02-23 | — | — | WO | claimed |
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| EP-1294698-A1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000626-A1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885OXTR 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.